Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.

Valentina CitiMarzia Del ReAlma MartelliVincenzo CalderoneMaria Cristina BreschiRomano Danesi

Published in: Cancer chemotherapy and pharmacology (2018)

Cellular levels of p-AKT(Ser473/Thr308) and p-ERK1/2(Thr202/Tyr204), activating mutations of PIK3CA and inactivating mutations of PTEN may predict response to everolimus in breast cancer cells; these findings have potential applications for treatment personalization of everolimus in breast cancer patients.

Keyphrases

signaling pathway
cell proliferation
pi k akt
breast cancer cells
protein kinase
risk assessment